Winton Group’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-10,623
| Closed | -$4.82M | – | 1389 |
|
|
2025
Q4 | $4.82M | Buy |
+10,623
| New | +$4.58M | 0.17% | 189 |
|
|
2025
Q1 | – | Sell |
-6,884
| Closed | -$2.77M | – | 802 |
|
|
2024
Q4 | $2.77M | Sell |
6,884
-624
| -8% | -$289K | 0.18% | 134 |
|
|
2024
Q3 | $3.49M | Buy |
+7,508
| New | +$3.61M | 0.24% | 105 |
|
|
2024
Q1 | – | Sell |
-8,521
| Closed | -$3.47M | – | 891 |
|
|
2023
Q4 | $3.47M | Buy |
8,521
+6,944
| +440% | +$2.57M | 0.25% | 58 |
|
|
2023
Q3 | $548K | Buy |
1,577
+327
| +26% | +$114K | 0.05% | 219 |
|
|
2023
Q2 | $440K | Sell |
1,250
-10,161
| -89% | -$3.42M | 0.04% | 382 |
|
|
2023
Q1 | $3.6M | Buy |
11,411
+298
| +3% | +$89.4K | 0.22% | 85 |
|
|
2022
Q4 | $3.21M | Buy |
11,113
+5,574
| +101% | +$1.7M | 0.21% | 92 |
|
|
2022
Q3 | $1.6M | Sell |
5,539
-12,597
| -69% | -$3.62M | 0.1% | 264 |
|
|
2022
Q2 | $5.11M | Sell |
18,136
-5,414
| -23% | -$1.45M | 0.27% | 68 |
|
|
2022
Q1 | $6.15M | Buy |
23,550
+7,753
| +49% | +$1.84M | 0.32% | 50 |
|
|
2021
Q4 | $3.47M | Buy |
15,797
+12,962
| +457% | +$2.52M | 0.21% | 82 |
|
|
2021
Q3 | $514K | Buy |
2,835
+302
| +12% | +$59K | 0.03% | 847 |
|
|
2021
Q2 | $511K | Buy |
2,533
+468
| +23% | +$97.9K | 0.03% | 910 |
|
|
2021
Q1 | $444K | Buy |
2,065
+89
| +5% | +$19.5K | 0.03% | 949 |
|
|
2020
Q4 | $467K | Sell |
1,976
-2,510
| -56% | -$576K | 0.03% | 828 |
|
|
2020
Q3 | $1.22M | Sell |
4,486
-12,004
| -73% | -$3.31M | 0.04% | 728 |
|
|
2020
Q2 | $4.79M | Buy |
16,490
+14,027
| +570% | +$3.8M | 0.12% | 228 |
|
|
2020
Q1 | $586K | Buy |
+2,463
| New | +$565K | 0.02% | 983 |
|
|
2019
Q2 | – | Sell |
-1,708
| Closed | -$314K | – | 1293 |
|
|
2019
Q1 | $314K | Sell |
1,708
-288
| -14% | -$53.2K | 0.01% | 787 |
|
|
2018
Q4 | $331K | Buy |
+1,996
| New | +$346K | 0.01% | 627 |
|
|
2018
Q2 | – | Sell |
-1,474
| Closed | -$240K | – | 1166 |
|
|
2018
Q1 | $240K | Sell |
1,474
-196
| -12% | -$32K | 0.01% | 1059 |
|
|
2017
Q4 | $250K | Sell |
1,670
-54,967
| -97% | -$8.14M | 0.01% | 637 |
|
|
2017
Q3 | $8.61M | Buy |
56,637
+52,675
| +1,330% | +$7.93M | 0.27% | 94 |
|
|
2017
Q2 | $511K | Buy |
+3,962
| New | +$477K | 0.02% | 500 |
|
Other funds holding VRTX
Winton Group's VRTX Position: Q1 2026 in Review
Winton Group sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 10,623 shares — an estimated $4.82M sold.
Winton Group first reported a position in VRTX in Q2 2017 and held it in 25 quarters. The position peaked at $8.61M in Q3 2017. 1,695 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Winton Group reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Winton Group sold 10,623 Vertex Pharmaceuticals shares in Q1 2026, an estimated $4.82M.
- Winton Group first reported a position in Vertex Pharmaceuticals in Q2 2017 and held it in 25 quarters.
- Winton Group's Vertex Pharmaceuticals position peaked at $8.61M in Q3 2017.
- 1,695 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Winton Group's 13F filing for Q1 2026, filed 12 May 2026.